Treatment for Low Protein S Level in Obstetric Patients
For pregnant women with protein S deficiency and no prior VTE history, antepartum clinical surveillance is recommended, with postpartum prophylaxis using LMWH or vitamin K antagonists for 6 weeks if there is a positive family history of VTE. 1, 2
Risk Stratification Approach
The management of protein S deficiency in pregnancy depends critically on three factors:
1. Prior VTE History
- No prior VTE: Clinical surveillance during pregnancy is generally sufficient
- Prior VTE: More aggressive prophylaxis is warranted
2. Family History of VTE
- Positive family history (first-degree relative with VTE before age 50): Increases risk substantially and changes management
- No family history: Lower risk profile
3. Additional Risk Factors
Consider the presence of obesity (BMI ≥30), smoking, preeclampsia, emergency cesarean section, or other thrombophilic conditions
Specific Management Recommendations
Antepartum Period
For protein S deficiency alone without prior VTE:
- Clinical surveillance is recommended regardless of family history 1, 2
- This means monitoring for signs/symptoms of VTE without routine pharmacologic prophylaxis
- Recent research suggests LMWH may improve live birth rates (100% vs 53.3% without treatment), particularly in women with recurrent pregnancy loss 3
Important caveat: The 2018 ASH guidelines note that protein S deficiency combined with other thrombophilic defects significantly increases VTE recurrence risk 1. If multiple thrombophilias are present, seek expert consultation and strongly consider prophylactic LMWH or UFH 1.
Postpartum Period
The postpartum period carries the highest VTE risk. Management depends on family history:
With positive family history of VTE:
- Prophylactic- or intermediate-dose LMWH for 6 weeks 2
- Alternative: Vitamin K antagonists (warfarin) targeted at INR 2.0-3.0 for 6 weeks 2
- Note: Vitamin K antagonists are safe during breastfeeding but should NOT be used in women who are protein S deficient according to some guidelines 2
Without family history of VTE:
- Clinical surveillance may be sufficient 2
- However, if ≥2 additional risk factors are present (emergency cesarean, postpartum hemorrhage >1L, preeclampsia, etc.), consider prophylaxis for 6 weeks 1
Practical Dosing
When LMWH is indicated:
- Prophylactic dose: Enoxaparin 40 mg subcutaneous daily or equivalent
- Intermediate dose: Enoxaparin 40 mg subcutaneous twice daily or equivalent
- Discontinue at least 24 hours before planned delivery or neuraxial anesthesia 2
- Resume 1 hour after epidural catheter removal 4
Critical Pitfalls to Avoid
Physiologic protein S decline: Protein S naturally decreases to 40-50% of normal during pregnancy 5. Do not overinterpret low levels measured during pregnancy—confirm deficiency postpartum.
Timing of anticoagulation around delivery: Must balance VTE risk against epidural hematoma risk. Ensure TTPA is within normal range before neuraxial procedures 4.
Distinguishing isolated protein S deficiency from combined thrombophilias: The presence of multiple defects substantially increases risk and may warrant more aggressive prophylaxis 6.
Postpartum period is highest risk: Even without antepartum prophylaxis, postpartum coverage is essential, particularly with family history 2.
Evidence Quality Note
The 2018 ASH guidelines 1 provide the most recent recommendations but acknowledge very low certainty in evidence. The 2012 CHEST guidelines 2 offer similar recommendations with Grade 2C evidence (weak recommendation, low-quality evidence). Recent observational data 3 suggests potential benefit of LMWH for pregnancy outcomes, but this requires confirmation in larger trials.